Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07096258

EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer) Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Université de Lorraine, Nancy, Lorraine, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease.
  • Intention-to-initiate first-line tumour therapy for this advanced disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  • At least 18 years of age on the day of signing informed consent, and capable of signing informed consent.

Exclusion criteria

  • Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.

Treatment and study plan

Primary outcomes

  1. Actionable biomarkers

    Time frame: At baseline

    Proportion of patients with successful molecular profiling and detectable actionable biomarkers

Study contacts

Contact information is provided by the study sponsor or research team.

Dr. Christian Meisel, MD PhD

CONTACT

[email protected]

+41 21 588 16 54

Sponsors and collaborators

Lead sponsor

Hedera Dx SA

Industry

Registry information

Official study title

A Patient Registry Collecting the Clinical and Molecular Profiling Data of Patients With Locally Advanced and/or Metastatic, Unresectable, Stages IIIB/C or IV Non-small Cell Lung Cancer (NSCLC), Who Have Not Previously Been Treated for This Advanced Disease and Are Therefore Considered as Patients Receiving First-line Therapy.

Acronym: EMPATHY NSCLC

Important dates

Study start
2024
Primary completion
2027
Study completion
2031
First posted
Jul 31, 2025
Registry last updated
Jul 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.